Endo Inc., a prominent player in the pharmaceutical and medical device industry, is headquartered in the United States. Founded in 1997, the company has established itself as a leader in pain management, urology, and other therapeutic areas, with a strong operational presence across North America and Europe. Endo Inc. is renowned for its innovative products, including advanced pain relief medications and minimally invasive surgical devices, which are designed to improve patient outcomes. The company’s commitment to quality and efficacy has earned it a significant market position, marked by notable achievements in research and development. With a focus on addressing unmet medical needs, Endo Inc. continues to drive advancements in healthcare, making a meaningful impact on patients' lives.
How does Endo Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Endo Inc.'s score of 27 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Endo Inc. reported total carbon emissions of approximately 64,067,000 kg CO2e, comprising 14,557,000 kg CO2e from Scope 1 and 49,401,000 kg CO2e from Scope 2 emissions. This marks a slight increase from 2023, where emissions were about 59,785,000 kg CO2e, with Scope 1 at 13,435,000 kg CO2e and Scope 2 at 45,570,000 kg CO2e. Over the past few years, Endo Inc. has shown a trend of fluctuating emissions, with 2022 emissions recorded at approximately 48,298,000 kg CO2e (12,718,000 kg CO2e from Scope 1 and 36,208,000 kg CO2e from Scope 2) and 2021 emissions at about 60,597,000 kg CO2e (16,872,000 kg CO2e from Scope 1 and 43,967,000 kg CO2e from Scope 2). The highest emissions in the last five years were in 2019, with a total of approximately 64,200,000 kg CO2e (27,475,000 kg CO2e from Scope 1 and 37,395,000 kg CO2e from Scope 2). Endo Inc. has not set specific reduction targets or initiatives as part of their climate commitments, and there are no emissions data reported for Scope 3. The company’s emissions data is not cascaded from any parent organisation, indicating that all reported figures are directly from Endo Inc. Overall, while Endo Inc. has made strides in tracking its emissions, the absence of reduction targets suggests a need for further commitment to climate action.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Endo Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.